Glucotrack reports Q3 net loss of $15.8 million on $7.9 million cash balance
Glucotrack Inc. reported a net loss of $15.8 million, or $30.1 per share, for the nine months ended September 30, 2025, compared to a net loss of $12.5 million, or $2,868 per share, for the same period in 2024. The increase in net loss was primarily due to higher general and administrative expenses and non-cash fair value changes in derivative liabilities. Marketing and general and administrative expenses were $4.4 million, up from $2.9 million a year earlier. Cash and cash equivalents as of September 30, 2025, were $7.9 million, compared to $5.6 million at December 31, 2024. During the period, Glucotrack secured $3 million in funding through a note purchase agreement and expanded its clinical advisory team. The company plans to submit an Investigational Device Exemption to the FDA for its continuous blood glucose monitor technology in spring 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-022305), on November 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.